Xencor, Inc. (NASDAQ:XNCR) Director Sells $27,595.46 in Stock

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) Director Richard J. Ranieri sold 2,993 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the sale, the director now directly owns 19,183 shares in the company, valued at approximately $176,867.26. The trade was a 13.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Xencor Stock Down 1.5%

NASDAQ:XNCR traded down $0.14 during trading hours on Monday, hitting $9.05. The company's stock had a trading volume of 570,953 shares, compared to its average volume of 667,223. Xencor, Inc. has a 52-week low of $7.16 and a 52-week high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $644.10 million, a P/E ratio of -2.83 and a beta of 0.87. The stock has a fifty day moving average of $9.08 and a 200-day moving average of $14.92.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. The company's revenue was up 104.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.11) EPS. On average, equities analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current year.

Analyst Ratings Changes

XNCR has been the subject of a number of research reports. Wells Fargo & Company dropped their price objective on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Barclays lowered their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. William Blair initiated coverage on shares of Xencor in a research note on Monday, April 21st. They set an "outperform" rating on the stock. Wedbush reissued an "outperform" rating and issued a $31.00 price objective on shares of Xencor in a research note on Wednesday, April 30th. Finally, Wall Street Zen lowered shares of Xencor from a "hold" rating to a "sell" rating in a report on Friday, March 14th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Xencor has a consensus rating of "Moderate Buy" and a consensus price target of $28.00.

Institutional Trading of Xencor

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Yousif Capital Management LLC boosted its holdings in shares of Xencor by 10.2% in the 4th quarter. Yousif Capital Management LLC now owns 20,976 shares of the biopharmaceutical company's stock valued at $482,000 after buying an additional 1,944 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in Xencor by 13.0% in the fourth quarter. Louisiana State Employees Retirement System now owns 33,800 shares of the biopharmaceutical company's stock valued at $777,000 after acquiring an additional 3,900 shares during the last quarter. Rhumbline Advisers lifted its position in Xencor by 11.7% in the fourth quarter. Rhumbline Advisers now owns 170,000 shares of the biopharmaceutical company's stock valued at $3,907,000 after acquiring an additional 17,743 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Xencor by 16.5% in the fourth quarter. Principal Financial Group Inc. now owns 340,145 shares of the biopharmaceutical company's stock valued at $7,817,000 after acquiring an additional 48,229 shares in the last quarter. Finally, Sanctuary Advisors LLC grew its holdings in shares of Xencor by 5.3% during the fourth quarter. Sanctuary Advisors LLC now owns 28,263 shares of the biopharmaceutical company's stock worth $649,000 after purchasing an additional 1,432 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.